Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis

Journal of Korean Medical Science

Volumn 23, Issue 3, 2008, Pages 439-444

  Shin, Ho Jin ^a,c   Joo, Seop Chung ^a,c   Lee, Je Jung ^b   Sang, Kyun Sohn ^d   Young, Jin Choi ^a,c   Kim, Yeo Kyeoung ^b   Yang, Deok Hwan ^b   Kim, Hyeoung Joon ^b   Jong, Gwang Kim ^d   Young, Don Joo ^e   Won, Sik Lee ^e   Sohn, Chang Hak ^e   Eun, Yup Lee ^a   Goon, Jae Cho ^a,b,f  

^a Pusan National University School of Medicine   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^d Kyungpook National University Hospital   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Pusan National University Hospital   (South Korea)

Author keywords

CHOP protocol; Herpesvirus 4, human; Lymphohistiocytosis, hemophagocytic; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CHOP PROTOCOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; FEMALE; FOLLOW UP; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; MALE; MIDDLE AGED; REMISSION; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 46849090930     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2008.23.3.439     Document Type: Article

References (15)

1. Janka GE, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol 2004; 124: 4-14.
2. Miyahara M, Sano M, Shibata K, Matsuzaki M, Ibaraki K, Shimamoto Y, Tokunaga O. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics. Ann Hematol 2000; 79: 378-88.
3. Imashuku S, Hibi S, Ohara T, Iwai A, Sako M, Kato M, Arakawa H, Sotomatsu M, Kataoka S, Asami K, Hasegawa D, Kosaka Y, Sano K, Igarashi N, Maruhashi K, Ichimi R, Kawasaki H, Maeda N, Tanizawa A, Arai K, Abe T, Hisakawa H, Miyashita H, Henter JI. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood 1999; 93: 1869-74.
4. Gencik A, Signer E, Muller H. Genetic analysis of familial erythrophagocytic lymphohistiocytosis. Eur J Pediatr 1984; 142: 248-52.
5. Henter JI, Arico M, Egeler RM, Elinder G, Favara BE, Filipovich AH, Gadner H, Imashuku S, Janka-Schaub G, Komp D, Ladisch S, Webb D. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study group of the Histiocyte Society. Med Pediatr Oncol 1997; 28: 342-7.
6. Kaito K, Kobayashi M, Katayama T, Otsubo H, Ogasawara Y, Sekita T, Saeki A, Sakamoto M, Nishiwaki K, Masuoka H, Shimada T, Yoshida M, Hosoya T. Prognostic factors of hemophagocytic syndrome in adults: analysis of 34 cases. Eur J Haematol 1997; 59: 247-53.
7. Imashuku S. Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 2002; 44: 259-72.
8. Su IJ, Wang CH, Cheng AL, Chen RL. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk Lymphoma 1995; 19: 401-6.
9. Dolezal MV, Kamel OW, van de Rijn M, Cleary ML, Sibley RK, Warnke RA. Virus-associated hemophagocytic syndrome characterized by clonal Epstein-Barr virus genome. Am J Clin Pathol 1995; 103: 189-94.
10. Chen JS, Tzeng CC, Tsao CJ, Su WC, Chen TY, Jung YC, Su IJ. Clonal karyotype abnormalities in EBV-associated hemophagocytic syndrome. Haematologica 1997; 82: 572-6.
11. Ito E, Kitazawa J, Arai K, Otomo H, Endo Y, Imashuku S, Yokoyama M. Fatal Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis with clonal karyotype abnormality. Int J Hematol 2000; 71: 263-5.
12. Yagita M, Iwakura H, Kishimoto T, Okamura T, Kunitomi A, Tabata R, Konaka Y, Kawa K. Successful allogeneic stem cell transplantation from an unrelated donor for aggressive Epstein-Barr virus-associated clonal T-cell proliferation with hemophagocytosis. Int J Hematol 2001; 74: 451-4.
13. Imashuku S, Kuriyama K, Teramura T, Ishii E, Kinugawa N, Kato M, Sako M, Hibi S. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19: 2665-73.
14. Imashuku S, Kuriyama K, Sakai R, Nakao Y, Masuda S, Yasuda N, Kawano F, Yakushijin K, Miyagawa A, Nakao T, Teramura T, Tabata Y, Morimoto A, Hibi S. Treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in young adults: a report from the HLH study center. Med Pediatr Oncol 2003; 41: 103-9.
15. Ise M, Sakai C, Tsujimura H, Kumagai K, Takenouchi T, Takagi T. Successful treatment with CPT-11 and adriamycin for hemophagocytic syndrome associated with intravascular lymphomatosis. Rinsho Ketsueki 1998; 39: 1131-6.